- Home
- APRE vs AQMS Comparison
APRE vs AQMS Comparison
Compare APRE & AQMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- AQMS
- Stock Information
- Founded
- APRE 2006
- AQMS 2014
- Country
- APRE United States
- AQMS United States
- Employees
- APRE N/A
- AQMS N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- AQMS Metal Fabrications
- Sector
- APRE Health Care
- AQMS Industrials
- Exchange
- APRE Nasdaq
- AQMS Nasdaq
- Market Cap
- APRE 15.8M
- AQMS 17.8M
- IPO Year
- APRE 2019
- AQMS 2015
- Fundamental
- Price
- APRE $4.08
- AQMS $1.93
- Analyst Decision
- APRE Strong Buy
- AQMS Strong Buy
- Analyst Count
- APRE 2
- AQMS 2
- Target Price
- APRE $15.50
- AQMS $30.00
- AVG Volume (30 Days)
- APRE 33.0K
- AQMS 371.4K
- Earning Date
- APRE 11-07-2024
- AQMS 11-14-2024
- Dividend Yield
- APRE N/A
- AQMS N/A
- EPS Growth
- APRE N/A
- AQMS N/A
- EPS
- APRE N/A
- AQMS N/A
- Revenue
- APRE $1,310,839.00
- AQMS N/A
- Revenue This Year
- APRE $134.21
- AQMS N/A
- Revenue Next Year
- APRE N/A
- AQMS N/A
- P/E Ratio
- APRE N/A
- AQMS N/A
- Revenue Growth
- APRE 130.31
- AQMS 525.00
- 52 Week Low
- APRE $2.15
- AQMS $1.33
- 52 Week High
- APRE $8.85
- AQMS $14.14
- Technical
- Relative Strength Index (RSI)
- APRE 62.50
- AQMS 44.24
- Support Level
- APRE $3.34
- AQMS $1.96
- Resistance Level
- APRE $4.41
- AQMS $2.14
- Average True Range (ATR)
- APRE 0.43
- AQMS 0.23
- MACD
- APRE 0.04
- AQMS -0.04
- Stochastic Oscillator
- APRE 54.19
- AQMS 15.79
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About AQMS Aqua Metals Inc.
Aqua Metals Inc is engaged in the business of recycling Lead through a novel, proprietary and patent-pending process that it developed and named AquaRefining. The company's breakthrough, AquaRefining, delivers a product, at a higher yield, eliminates toxic waste, reduces permitting and is less expensive to build than smelting. AquaRefining process will provide for the recycling of Lead acid batteries and the production of a pure grade Lead with a significantly lower cost of production, and with fewer environmental and regulatory issues, than conventional methods of Lead production.